Zai Lab downgraded by BofA Securities with a new price target
$ZLAB
Biotechnology: Pharmaceutical Preparations
Health Care
BofA Securities downgraded Zai Lab from Buy to Neutral and set a new price target of $36.10 from $29.00 previously
Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
3/7/2025 | $55.00 | Sector Outperform | Scotiabank |
3/3/2025 | $29.00 → $36.10 | Buy → Neutral | BofA Securities |
12/14/2023 | $47.50 | Overweight | Morgan Stanley |
8/10/2023 | $70.00 | Overweight | Cantor Fitzgerald |
3/2/2022 | $194.00 → $102.00 | Outperform | SVB Leerink |
1/21/2022 | $64.00 | Outperform | Macquarie |
12/15/2021 | $189.00 → $136.00 | Overweight | JP Morgan |
11/11/2021 | $222.00 → $217.00 | Buy | Citigroup |